Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ascendis Pharma ADR (NQ: ASND )

135.90 -1.03 (-0.75%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 226,133
Open 137.00
Bid (Size) 121.00 (1)
Ask (Size) 217.26 (2)
Prev. Close 136.93
Today's Range 133.39 - 139.81
52wk Range 66.03 - 161.00
Shares Outstanding 57,152,295
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Looking Into Ascendis Pharma's Recent Short Interest
Via Benzinga
$1000 Invested In Ascendis Pharma 15 Years Ago Would Be Worth This Much Today
Via Benzinga

Performance

YTD
+6.56%
+6.56%
1 Month
-8.45%
-8.45%
3 Month
+2.60%
+2.60%
6 Month
+53.96%
+53.96%
1 Year
+76.54%
+76.54%

More News

Read More
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
Via Benzinga
Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today
Via Benzinga
5 Biotechnology Stocks To Buy For A Stable Portfolio In 2024
Via Talk Markets
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
Via Benzinga
How Is The Market Feeling About Ascendis Pharma?
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $70,000 Today
Via Benzinga
These Five Small-Cap Stocks Under The Radar Are Expected To Surge, Says Stock Researcher
Via Benzinga
Earnings Scheduled For February 7, 2024
Via Benzinga
Ascendis Pharma's Earnings: A Preview
Via Benzinga
$100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Recap: Ascendis Pharma Q3 Earnings
Via Benzinga
Preview: Ascendis Pharma's Earnings
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
The Latest Analyst Ratings for Ascendis Pharma
Via Benzinga
Impact on BioMarin's Sentiment: Voxzogo's Triumph Clouded by Uncertainty
Via Benzinga
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
From Royalty Pharma plc
Via GlobeNewswire
Earnings Scheduled For September 5, 2023
Via Benzinga
Earnings Preview For Ascendis Pharma
Via Benzinga
Analyst Expectations for Ascendis Pharma's Future
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Ascendis, Alvotech, Shift4, and Waldencast and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.